Search details
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Article
in English
| MEDLINE | ID: mdl-37256976
2.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol
; 23(7): 851-864, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35671774
3.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 21(3): 345-357, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32035020
4.
Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.
Lancet Oncol
; 21(5): e234, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32359499
5.
Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer.
PLoS One
; 18(1): e0280259, 2023.
Article
in English
| MEDLINE | ID: mdl-36649275
6.
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
NPJ Breast Cancer
; 7(1): 44, 2021 Apr 16.
Article
in English
| MEDLINE | ID: mdl-33863913
7.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Clin Cancer Res
; 26(15): 3947-3957, 2020 08 01.
Article
in English
| MEDLINE | ID: mdl-32312891
8.
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
; 26(7): 1574-1585, 2020 04 01.
Article
in English
| MEDLINE | ID: mdl-31836609
9.
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
J Clin Oncol
; 38(5): 423-433, 2020 02 10.
Article
in English
| MEDLINE | ID: mdl-31841354
10.
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Cancer Discov
; 10(10): 1528-1543, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32532747
11.
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
Cancer Chemother Pharmacol
; 81(5): 873-883, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29541803
12.
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Clin Cancer Res
; 24(9): 2050-2059, 2018 05 01.
Article
in English
| MEDLINE | ID: mdl-29066505
13.
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
; 28(24): 5469, 2022 Dec 15.
Article
in English
| MEDLINE | ID: mdl-36519303
14.
AKT Inhibition in Solid Tumors With AKT1 Mutations.
J Clin Oncol
; 35(20): 2251-2259, 2017 Jul 10.
Article
in English
| MEDLINE | ID: mdl-28489509
Results
1 -
14
de 14
1
Next >
>>